Johnson & Johnson Other Non-Current Liabilities 2010-2024 | JNJ
Johnson & Johnson other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Johnson & Johnson other non-current liabilities for the quarter ending September 30, 2024 were $15.277B, a 5.12% decline year-over-year.
- Johnson & Johnson other non-current liabilities for 2023 were $16.279B, a 12.64% increase from 2022.
- Johnson & Johnson other non-current liabilities for 2022 were $14.452B, a 11.87% decline from 2021.
- Johnson & Johnson other non-current liabilities for 2021 were $16.399B, a 11.37% decline from 2020.
Johnson & Johnson Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$16,279 |
| 2022 |
$14,452 |
| 2021 |
$16,399 |
| 2020 |
$18,503 |
| 2019 |
$19,178 |
| 2018 |
$16,831 |
| 2017 |
$17,489 |
| 2016 |
$9,536 |
| 2015 |
$10,241 |
| 2014 |
$8,034 |
| 2013 |
$7,854 |
| 2012 |
$8,552 |
| 2011 |
$10,631 |
| 2010 |
$6,567 |
| 2009 |
$5,947 |
Johnson & Johnson Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$15,277 |
| 2024-06-30 |
$14,427 |
| 2024-03-31 |
$17,948 |
| 2023-12-31 |
$16,279 |
| 2023-09-30 |
$16,102 |
| 2023-06-30 |
$17,118 |
| 2023-03-31 |
$18,717 |
| 2022-12-31 |
$14,452 |
| 2022-09-30 |
$14,080 |
| 2022-06-30 |
$14,686 |
| 2022-03-31 |
$16,242 |
| 2021-12-31 |
$16,399 |
| 2021-09-30 |
$16,947 |
| 2021-06-30 |
$18,446 |
| 2021-03-31 |
$18,509 |
| 2020-12-31 |
$18,503 |
| 2020-09-30 |
$18,894 |
| 2020-06-30 |
$17,625 |
| 2020-03-31 |
$18,346 |
| 2019-12-31 |
$19,178 |
| 2019-09-30 |
$18,874 |
| 2019-06-30 |
$17,645 |
| 2019-03-31 |
$17,002 |
| 2018-12-31 |
$16,831 |
| 2018-09-30 |
$17,075 |
| 2018-06-30 |
$17,928 |
| 2018-03-31 |
$18,329 |
| 2017-12-31 |
$17,489 |
| 2017-09-30 |
$9,102 |
| 2017-06-30 |
$10,117 |
| 2017-03-31 |
$9,526 |
| 2016-12-31 |
$9,536 |
| 2016-09-30 |
$9,414 |
| 2016-06-30 |
$10,062 |
| 2016-03-31 |
$9,749 |
| 2015-12-31 |
$10,241 |
| 2015-09-30 |
$9,303 |
| 2015-06-30 |
$8,973 |
| 2015-03-31 |
$8,604 |
| 2014-12-31 |
$8,034 |
| 2014-09-30 |
$7,758 |
| 2014-06-30 |
$7,373 |
| 2014-03-31 |
$7,271 |
| 2013-12-31 |
$7,854 |
| 2013-09-30 |
$8,895 |
| 2013-06-30 |
$8,569 |
| 2013-03-31 |
$8,197 |
| 2012-12-31 |
$8,552 |
| 2012-09-30 |
$9,207 |
| 2012-06-30 |
$9,487 |
| 2012-03-31 |
$10,538 |
| 2011-12-31 |
$10,631 |
| 2011-09-30 |
$7,473 |
| 2011-06-30 |
$7,227 |
| 2011-03-31 |
$7,001 |
| 2010-12-31 |
$6,567 |
| 2010-09-30 |
$6,226 |
| 2010-06-30 |
$6,359 |
| 2010-03-31 |
$6,043 |
| 2009-12-31 |
$5,947 |
| 2009-09-30 |
$5,054 |
| 2009-06-30 |
$4,275 |
| 2009-03-31 |
$4,148 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
